AbbVie Inc. Capex/Depreciation

Capex/Depreciation of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex/Depreciation growth rates and interactive chart.


Highlights and Quick Summary

  • Capex/Depreciation for the quarter ending December 30, 2019 was -0.32 (a 4.57% increase compared to previous quarter)
  • Year-over-year quarterly Capex/Depreciation increased by 50.54%
  • Annual Capex/Depreciation for 2019 was -0.27 (a -24.29% decrease from previous year)
  • Annual Capex/Depreciation for 2018 was -0.36 (a 2.58% increase from previous year)
  • Annual Capex/Depreciation for 2017 was -0.35 (a -12.53% decrease from previous year)
  • Twelve month Capex/Depreciation ending December 30, 2019 was -0.27 (a 4.23% increase compared to previous quarter)
  • Twelve month trailing Capex/Depreciation decreased by -20.3% year-over-year
Trailing Capex/Depreciation for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
-0.27 -0.26 -0.34 -0.34
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex/Depreciation of AbbVie Inc.

Most recent Capex/Depreciationof ABBV including historical data for past 10 years.

Interactive Chart of Capex/Depreciation of AbbVie Inc.

AbbVie Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -0.32 -0.31 -0.26 -0.21 -0.27
2018 -0.28 -0.65 -0.26 -0.27 -0.36
2017 -0.49 -0.33 -0.33 -0.25 -0.35
2016 -0.35 -0.37 -0.45 -0.45 -0.4
2015 -0.56 -0.56 -0.61 -0.92 -0.64
2014 -0.79 -0.94 -0.7 -0.69 -0.78
2013 -0.76 -0.57 -0.5 -0.39 -0.55
2012 -0.31 0.08 -0.32 -0.51 -0.29
2011 -0.32 -0.2 -0.29 -0.31 -0.28
2010 -0.38 -0.38
2009 -0.45 -0.45

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.